Loading organizations...
Hip Innovation Technology, LLC is a medical device company developing innovative hip replacement systems for joint reconstruction and hip arthroplasty, with operations referencing Boca Raton, Florida, and New Jersey. The company focuses on designing, manufacturing, and marketing reconstructive surgical products aimed at improving surgical outcomes and patient quality of life, particularly addressing hip instability complications in total hip arthroplasty. Its proprietary orthopedic products are developed for commercialization, with majority ownership held by Joint Innovation Technology, LLC. In January 2022, Hip received FDA Investigational Device Exemption (IDE) approval to initiate a landmark study for its Reverse Hip Replacement System, following a July 2022 presentation of data. Key figures include Founder and CEO George Diamantoni, President and Chief Medical Officer Dr. Zafer Termanini, and Scientific Development Board Chairman Joseph Zuckerman. Hip Innovation Technology was founded in 2011 by George Diamantoni.
Hip has raised $12.0M across 1 funding round.
Hip has raised $12.0M in total across 1 funding round.
Hip has raised $12.0M in total across 1 funding round.
Hip's investors include Magenta Venture Partners.
Hip has raised $12.0M across 1 funding round. Most recently, it raised $12.0M Series A in February 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 1, 2021 | $12M Series A | — | Magenta Venture Partners | Announced |
Hip Innovation Technology, LLC (HIT) is a privately held medical technology company founded in 2011, specializing in orthopedic device solutions, particularly innovative hip implants.[1][2] Its lead product, the Reverse Hip Replacement System (Reverse HRS), is a unique implant design aimed at optimizing existing hip systems while addressing unmet clinical needs in Total Hip Arthroplasty (THA), currently in clinical trials and not yet available for sale.[1][2] HIT serves patients and healthcare providers by advancing quality of life and care through differentiated features like state-of-the-art surgical instruments and a robust intellectual property portfolio exceeding 160 issued patents and 130 pending applications, protected through 2030.[1]
Headquartered in Boca Raton, Florida, as a subsidiary of Joint Innovation Technology, LLC, HIT focuses on breakthrough technologies in orthopedics with over four years of rigorous R&D.[1] This positions it in the growing medtech sector, emphasizing product differentiation amid rising demand for advanced joint replacement solutions.[1][2]
Hip Innovation Technology, LLC was formed in 2011 as a privately held entity dedicated to orthopedic innovations.[1][2] While specific founders are not detailed in available sources, the company's early commitment centered on developing market-leading devices, culminating in the Reverse HRS after rational design to enhance marketed hip systems and solve clinical gaps.[1] Pivotal moments include over four years of world-class device design, R&D, and building an extensive IP portfolio with 160+ issued patents, 130+ pending applications, and 61 design registrations.[1]
Corporate evolution includes establishing headquarters in Boca Raton, Florida, and operating as a subsidiary of Joint Innovation Technology, LLC, with ongoing clinical trials marking progress toward commercialization.[1][2]
HIT stands out in orthopedics through targeted innovations:
These elements provide competitive edges in clinical outcomes and market entry.[1]
HIT rides the trend of advanced orthopedic implants amid rising THA demand due to aging populations and active lifestyles, where unmet needs like implant stability and longevity persist.[1] Timing aligns with medtech's shift toward innovative designs and IP-protected breakthroughs, as traditional systems face limitations in addressing complications.[1][2]
Market forces favoring HIT include regulatory progress via clinical trials and a strong patent moat, enabling differentiation in a competitive field.[1] It influences the ecosystem by advancing THA standards, potentially reducing revision surgeries and improving care efficiency, while complementing digital tools like mixed-reality platforms in hip surgery.[1][5]
HIT's path forward hinges on Reverse HRS clinical trial success and FDA clearance, potentially launching a family of implants with superior features by late 2020s.[1] Trends like personalized orthopedics, additive manufacturing integration (e.g., HIP processing for implants), and digital surgery navigation will amplify its momentum, expanding addressable markets.[1][3][4][5]
Influence may evolve from developer to market leader if commercialization scales, tying back to its 2011 mission of transformative orthopedic solutions that elevate patient outcomes.[1][2]
